CRISPR enzyme from groundwater bacteria shows unusual properties
Chemical & Engineering News
|
February 10, 2019
X min read
Chemical & Engineering News
|
February 10, 2019
Share on Social
More like this
News
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
May 21, 2026
Read Now
Press
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
May 21, 2026
Read Now
News
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
May 18, 2026
Read Now
Press
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
May 18, 2026
Read Now
News
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
April 30, 2026
Read Now
Press
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
April 30, 2026
Read Now
